

09/763334
Rec'd PCT/PTC 06 AUG 2001

Express Mail No.: EL 501 641 199 US **H3**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Xu *et al.*

Application No.: 09/763,334

Group Art Unit: To be assigned

Filed: February 16, 2001 as National Stage
Application of PCT/US99/19068, filed
August 18, 1999

Examiner: To be assigned

Attorney Docket No.: 6523-020

For: TREATMENT AND PREVENTION OF
CANCER AND PITUITARY DISORDERS
WITH LATS PROTEINS, DERIVATIVES
AND FRAGMENTS, AND LATS
KNOCK-OUT ANIMAL MODELS

TRANSMITTAL OF SUBSTITUTE SEQUENCE LISTING UNDER 37 C.F.R. § 1.821

Assistant Commissioner for Patents
Washington, DC 20231

Sir:


In response to the Notification of Missing Requirements under 35 U.S.C. § 371 in the United States Designated/Elected Office (DO/EO/US) mailed March-28, 2001, Applicants submit herewith copies of a Substitute Sequence Listing in paper and computer readable forms. The Substitute Sequence Listing corrects inadvertent omissions discovered in the Sequence Listing filed on August 18, 1999 in connection with International Application PCT/US99/19068, of which the instant application is a national stage application.

Specifically, SEQ ID NO: 7, which corresponds to the *Drosophila lats* nucleotide sequence depicted in Figure 15, has been corrected to list the base variations, introns, and poly-A signal that are depicted in the *lats* nucleotide sequence of Figure 15. SEQ ID NO: 8, which corresponds to the *Drosophila lats* amino acid sequence depicted in Figure 15, has been corrected to list the amino acid variations that are depicted in the *lats* amino sequence of Figure 15. New SEQ ID NO: 9 has been added, which corresponds to mouse *lats* amino acid sequence (m-*lats*, partial sequence) depicted in Figure 6A. No new matter has been added.

I hereby state that the content of the paper and computer readable copies of the Substitute Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same. I hereby state that the submission herein under 37 C.F.R. § 1.821(g) does not include new matter.

Respectfully submitted,

Date: August 6, 2001


Geraldine F. Baldwin 31,232
(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090
Attorneys For Applicants

Enclosures